FDA greenlights early-stage trial of VectorY’s first-in-class therapy targeting the core biology driving most ALS cases. Netherlands-based biotech VectorY Therapeutics…
Early biomarker engagement and clean safety data position VNA-318 as a potential new entrant in longevity-focused neurotherapeutics. Vandria has reported…
Longevity biotech seeks to broaden its therapeutic capabilities with cellular reprogramming and delivery technologies. Longevity-focused biotech Klotho Neurosciences revealed it…
